Tol J - Search Results

1

Quality of integrated female oncofertility care is suboptimal: A patient-reported measurement.

van den Berg M, Kaal SEJ, Schuurman TN, Braat DDM, Mandigers CMPW, Tol J, Tromp JM, van der Vorst MJDL, Beerendonk CCM, Hermens RPMG. van den Berg M, et al. Among authors: tol j. Cancer Med. 2023 Feb;12(3):2691-2701. doi: 10.1002/cam4.5149. Epub 2022 Aug 29. Cancer Med. 2023. PMID: 36031940 Free PMC article.

2

Selecting the optimal position of CDK4/6 inhibitors in hormone receptor-positive advanced breast cancer - the SONIA study: study protocol for a randomized controlled trial.

van Ommen-Nijhof A, Konings IR, van Zeijl CJJ, Uyl-de Groot CA, van der Noort V, Jager A, Sonke GS; SONIA study steering committee. van Ommen-Nijhof A, et al. BMC Cancer. 2018 Nov 20;18(1):1146. doi: 10.1186/s12885-018-4978-1. BMC Cancer. 2018. PMID: 30458732 Free PMC article.

3

Perspectives of patients with metastatic breast cancer on physical exercise programs: results from a survey in five European countries.

Sweegers MG, Depenbusch J, Kampshoff CS, Aaronson NK, Hiensch A, Wengström Y, Backman M, Gunasekara N, Clauss D, Pelaez M, Lachowicz M, May AM, Steindorf K, Stuiver MM; PERSPECTIVE survey group. Sweegers MG, et al. Support Care Cancer. 2023 Nov 13;31(12):694. doi: 10.1007/s00520-023-08124-4. Support Care Cancer. 2023. PMID: 37955790 Free PMC article.

4

MRI-guided optimisation of neoadjuvant chemotherapy duration in stage II-III HER2-positive breast cancer (TRAIN-3): a multicentre, single-arm, phase 2 study.

van der Voort A, Louis FM, van Ramshorst MS, Kessels R, Mandjes IA, Kemper I, Agterof MJ, van der Steeg WA, Heijns JB, van Bekkum ML, Siemerink EJ, Kuijer PM, Scholten A, Wesseling J, Vrancken Peeters MTFD, Mann RM, Sonke GS; Dutch Breast Cancer Research Group. van der Voort A, et al. Lancet Oncol. 2024 May;25(5):603-613. doi: 10.1016/S1470-2045(24)00104-9. Epub 2024 Apr 5. Lancet Oncol. 2024. PMID: 38588682 Clinical Trial.

5

Caution for interstitial lung disease as a cause of CA 15-3 rise in advanced breast cancer patients treated with everolimus.

Willemsen AE, Grutters JC, Gerritsen WR, Tol J, van Herpen CM. Willemsen AE, et al. Among authors: tol j. Int J Cancer. 2014 Aug 15;135(4):1007. doi: 10.1002/ijc.28714. Epub 2014 Jan 17. Int J Cancer. 2014. PMID: 24415627 Free article. No abstract available.

6

Neutrophil Recovery in Breast Cancer Patients Receiving Docetaxel-Containing Chemotherapy with and without Granulocyte Colony-Stimulating Factor Prophylaxis.

Aarts MJ, Vriens BE, de Boer M, Peters FP, Mandigers CM, Dercksen MW, Stouthard JM, Tol J, van Warmerdam LJ, van de Wouw AJ, Jacobs EM, van der Rijt CCD, Smilde TJ, van der Velden AW, Peer N, Tjan-Heijnen VCG. Aarts MJ, et al. Among authors: tol j. Oncology. 2017;93(5):323-328. doi: 10.1159/000479067. Epub 2017 Aug 22. Oncology. 2017. PMID: 28848182

7

Current questions in the treatment of advanced colorectal cancer: the CAIRO studies of the Dutch Colorectal Cancer Group.

Simkens L, Tol J, Koopman M, Mol L, Antonini N, van Krieken H, Punt C. Simkens L, et al. Among authors: tol j. Clin Colorectal Cancer. 2008 Mar;7(2):105-9. doi: 10.3816/CCC.2008.n.014. Clin Colorectal Cancer. 2008. PMID: 18501069 Review.

8

Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab.

Tol J, Dijkstra JR, Klomp M, Teerenstra S, Dommerholt M, Vink-Börger ME, van Cleef PH, van Krieken JH, Punt CJ, Nagtegaal ID. Tol J, et al. Eur J Cancer. 2010 Jul;46(11):1997-2009. doi: 10.1016/j.ejca.2010.03.036. Epub 2010 Apr 21. Eur J Cancer. 2010. PMID: 20413299 Clinical Trial.

9

The effect of prophylactic calcium and magnesium infusions on the incidence of neurotoxicity and clinical outcome of oxaliplatin-based systemic treatment in advanced colorectal cancer patients.

Knijn N, Tol J, Koopman M, Werter MJ, Imholz AL, Valster FA, Mol L, Vincent AD, Teerenstra S, Punt CJ. Knijn N, et al. Among authors: tol j. Eur J Cancer. 2011 Feb;47(3):369-74. doi: 10.1016/j.ejca.2010.10.006. Epub 2010 Nov 8. Eur J Cancer. 2011. PMID: 21067912 Clinical Trial.

10

KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients.

Knijn N, Mekenkamp LJ, Klomp M, Vink-Börger ME, Tol J, Teerenstra S, Meijer JW, Tebar M, Riemersma S, van Krieken JH, Punt CJ, Nagtegaal ID. Knijn N, et al. Among authors: tol j. Br J Cancer. 2011 Mar 15;104(6):1020-6. doi: 10.1038/bjc.2011.26. Epub 2011 Mar 1. Br J Cancer. 2011. PMID: 21364579 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

420 results

Search Page